We assess the levels of TRIM21 and IL-6 in the context of anti-Ro autoantibody status, and in different symptom-based pSS subgroups we have previously described, to explore whether they may contribute to the clinical heterogeneity in pSS. Here, TRIM21 is linked to peeling skin syndrome.